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Abstract The diagnosis of Lyme borreliosis is challenging
because of the often non-specific symptoms and persisting
antibodies after infection.We investigated the diagnostic char-
acteristics of two enzyme-linked immunosorbent assays
(ELISAs) and an immunoblot for the detection of Borrelia-
specific serum antibodies using different test strategies in in-
dividuals with and without antibiotic treatment for Lyme
borreliosis. This retrospective study included healthy individ-
uals, patients with active Lyme neuroborreliosis and patients
treated for Lyme neuroborreliosis. Two ELISAs were com-
pared: the C6 ELISA and the SERION ELISA. Equivocal
and positive results were confirmed by immunoblot. We in-
cluded 174 healthy individuals, of whom 27 (15.5%) were
treated for Lyme borreliosis in the past, 36 patients were treat-
ed for Lyme neuroborreliosis and 27 patients had active Lyme
neuroborreliosis. All the active Lyme neuroborreliosis patients
were reactive in both ELISAs (100% sensitivity); less reactivity
was seen in the other three groups (range 17.7% to 69.4%). The
concordance between the ELISA results was high in active
Lyme neuroborreliosis patients (26/27; 96.3%) and healthy indi-
viduals (131/147; 89.1%), but lower in treated healthy individ-
uals (18/27; 66.7%) and treated Lyme neuroborreliosis patients
(18/36; 50.0%) (p ≤ 0.005). This study showed that antibiotic
treatment against Lyme borreliosis was strongly associated with
discordant ELISA and test strategy results (odds ratio: 10.52; p <
0.001 and 9.98; p = 0.014, respectively) suggesting antibiotic
treatment influences the pace at which the various antibodies
directed to the different antigens used in both ELISAs wane.
Among treated neuroborreliosis patients, the SERION ELISA
stayed positive for a longer period after infection compared to
the C6 ELISA. This should be taken into consideration when
requesting and/or interpreting Lyme serology.
Introduction
The recommended approach for the diagnosis of Lyme
borreliosis consists of screening for Borrelia-specific se-
rum antibodies with an enzyme-linked immunosorbent as-
say (ELISA), followed by immunoblot confirmation of
equivocal or positive ELISA results [1]. The reliability of
the serodiagnosis of Lyme borreliosis is influenced by var-
ious factors, including the manifestation and the duration
of disease, the natural clearance of infection, antibiotic
treatment, (age-specific) seroprevalence and the test char-
acteristics, such as the antigens used [2]. Antibiotic therapy
can abrogate the immune response, but the persistence of
Borrelia-specific serum antibodies up to several years after
antibiotic treatment has also been reported [3, 4]. In the
Dutch population, the seroprevalence is 4–8%, but is higher
in certain risk groups, such as forestry workers (20%) [5, 6].
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These seropositive cases are usually asymptomatic, suggest-
ing a cleared infection with the persistence of Borrelia-specif-
ic serum antibodies.
A large variety of diagnostic assays for Lyme borreliosis is
available. Some assays make use of whole-cell lysates, which
are mostly derived from cultured Borrelia burgdorferi sensu
stricto, Borrelia afzelii or Borrelia garinii [7, 8]. These assays
have a potential problem of higher cross-reactivity with com-
mon antigens of other micro-organisms [9]. Recombinant an-
tigens, such as OspC, DbpA [10, 11] and especially VlsE
(Vmp-like sequence) and C6 peptide are more specific [12,
13]. Although studies have compared different assays using
different test strategies, these studies lacked well-defined
study populations [14].
Therefore, we usedwell-described patient groups as well as
healthy individuals to compare two standard two-tier test strat-
egies, based on an ELISA (either the C6 ELISA or the
SERION ELISA), followed by immunoblot confirmation of
equivocal and positive ELISA results. The C6 ELISA mea-
sures total immunoglobulin to a recombinant C6 peptide and
is currently used in our laboratory. The SERION ELISA mea-
sures IgM and IgG to two whole-cell lysates of B. burgdorferi
sensu lato. It is an improved version compared to the
one used by Smismans et al. [8] by the addition of
recombinant VlsE for the detection of IgG. The SERION
ELISA was selected because it is based on different antigens
and it uses VlsE instead of the C6 peptide. VlsE evokes a
different antibody response compared to the C6 peptide, since
the C6 peptide only becomes available after a conformational
change of VlsE when Borrelia enters the human body [12,
15]. A third test strategy was also included and consisted of
a more unconventional approach based on the combination of
both ELISAs as a screening test and immunoblot confirmation
of all results, except concordant negative results.
Materials and methods
Study population
To qualify for inclusion in this study, all healthy individuals and
(hospital) patients had to be ≥18 years old. Healthy individuals,
with an increased risk of a tick bite, were recruited in the period
between February 2013 and December 2015. Most healthy
individuals consisted of personnel of the Diakonessenhuis
Hospital or the St. Antonius Hospital, both located in the centre
of the Netherlands, close to forested areas. In the same period,
Boy Scout patrol leaders, owners of hunting dogs, recreational
runners and personnel of the National Institute for Public
Health and the Environment (RIVM), all with recreational ac-
tivities in high-risk areas for tick bites, were asked to partici-
pate. Healthy individuals who mentioned antibiotic treatment
for Lyme borreliosis in the past in their questionnaire were
included in a separate group, referred to as treated healthy in-
dividuals. Lyme neuroborreliosis patients enrolled in this study
had to fulfil at least two of the following criteria, as proposed by
the European Federation of Neurological Societies (EFNS): (i)
the presence of neurological symptoms suggestive of Lyme
neuroborreliosis without other obvious explanations, (ii) cere-
brospinal fluid (CSF) pleocytosis (≥5 leucocytes/μL) and/or
(iii)Borrelia-specific intrathecal antibody production. A patient
was diagnosed with definite Lyme neuroborreliosis when all
three criteria weremet andwith possible Lyme neuroborreliosis
when two criteria were fulfilled [16] and they had either been
treated for Lyme neuroborreliosis in the past or were recently
diagnosedwith (active) Lyme neuroborreliosis. For inclusion in
the study, intrathecal IgM/IgG was determined by the second-
generation IDEIA™ Lyme Neuroborreliosis test (Oxoid,
Cambridgeshire, United Kingdom). Patients who had been di-
agnosed and treated for Lyme neuroborreliosis between
February 2004 and September 2012 were enrolled from
March 2013 to March 2015; active Lyme neuroborreliosis pa-
tients were recruited from December 2010 to December 2015
and were only included if they had not yet started antibiotic
treatment for Lyme neuroborreliosis. Active Lyme
neuroborreliosis patients who had finished antibiotic treatment
could also be included as treated Lyme neuroborreliosis pa-
tients when at least one year had passed after their inclusion
as an active Lyme neuroborreliosis case.
All healthy individuals and patients were asked to fill in a
Lyme-specific questionnaire, which included questions regard-
ing tick bites, presence of erythema migrans (EM), antibiotic
treatment for Lyme borreliosis and (self-reported) complaints
at the moment of inclusion and during possible earlier episodes
of Lyme borreliosis. Information regarding the clinical symp-
toms, pleocytosis, intrathecal antibody production and the clin-
ical outcome (in case of treated Lyme neuroborreliosis pa-
tients) was extracted from the hospital information system.
Patients were considered to have a good recovery when, within
six months after antibiotic treatment finished, symptoms were
absent or had considerably decreased. Patients were consid-
ered as treatment failure if severe symptoms continued for
>6 months after they had finished antibiotic treatment.
Healthy individuals were only recruited when they reported
no complaints at the moment of inclusion.
Serology
Serum samples of all study subjects were tested in two ELISAs
and one immunoblot. All tests were performed according to the
manufacturer’s instructions using a DS2 automated ELISA
instrument (Dynex® DS2, Dynex Technologies, Chantilly,
VA, USA) and analysed with the DS-Matrix™ software
(Dynex Technologies). An ELISA result was called reactive
when the result was equivocal or positive [5]. When both IgG
and IgM were determined separately (SERION ELISA and
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immunoblot), the final result was based on a combination of
the results of both immunoglobulins; negative when both IgM
and IgG were negative, equivocal when at least one of these
was equivocal and positive when at least one of these was
positive. When immunoblot confirmation was performed, this
result determined the final serology result, independent of an
equivocal or positive ELISA result. The C6 ELISA was per-
formed immediately after blood sampling. Immunoblot con-
firmation was done ≤2 weeks after blood sampling for sam-
ples with C6 ELISA index scores between 0.91 to 3.00, ac-
cording to the protocol of our laboratory. For the purpose of
this study, the SERION ELISAwas performed on all samples
several months to years later. In addition, the samples with C6
ELISA index scores ≥3.00 and any additional reactive
SERION ELISA/negative C6 ELISA results were confirmed
with immunoblot. Blood samples were stored at 4 °C for two
weeks after blood sampling and at −20 °C for longer storage.
C6 ELISA
The C6 ELISA (Immunetics, Boston,MA, USA) is based on a
synthetic C6 peptide, which is derived from a highly immu-
nogenic part (invariable region 6) of the VlsE lipoprotein [13].
SERION ELISA
The SERION ELISA IgM and IgG tests (SERION ELISA
classic Borrelia burgdorferi IgM and IgG, Institute Virion/
Serion GmbH,Würzburg, Germany) are both based on a com-
bination of bacterial lysates of B. afzelii P-Ko [17] and
B. garinii [18]. For IgG detection, the lysates are enrichedwith
recombinant VlsE.
Immunoblot
RecomLine IgM and IgG strips (Mikrogen GmbH, Neuried,
Germany) containing purified recombinant B. burgdorferi
sensu lato antigens (OspA, OspC, p100, VlsE, p39, p58 and
p18) were used [19]. The results were measured with an au-
tomated recomScan system using the recomScan Software
(Mikrogen GmbH).
Test strategies
In this study, three different test strategies were compared. The
first two strategies were based on the recommended two-tier
test strategy; a screening ELISA followed by immunoblot (IB)
confirmation of equivocal or positive ELISA results [1]. The
C6 ELISAwas used as a screening assay in the first strategy
(C6/IB strategy) and the second strategy used the SERION
ELISA as a screening test (SE/IB strategy). The third strategy
was based on the two ELISAs followed by immunoblot
confirmation on all combinations of results, except concordant
negative results (SE + C6/IB strategy).
Statistical analysis
Dichotomous, unrelated samples were analysed using
Pearson’s Chi-squared test or Fisher’s exact test. Post-hoc tests
consisted of two-group comparisons using Pearson’s Chi-
squared test or Fisher’s exact test. The non-parametric
Cochran’s Q test for >2 related samples was used for compar-
ison of the ELISA and strategy results and post-hoc tests
consisted of theMcNemar’s test. For these statistical analyses,
equivocal results were combined with positive results.
Quantitative data were analysed using the Kruskal–Wallis test
for >2 group comparisons. Two-group comparisons and post-
hoc tests consisted of theMann–Whitney test. A p-value <0.05
was interpreted as statistically significant, unless Bonferroni
correction was applied; Bonferroni correction was applied to
all post-hoc tests. Concordance was determined between the
C6 ELISA and the SERION ELISA and between the C6/IB
strategy and the SE/IB strategy; concordance was calculated
as the number of matching positive, equivocal and negative
results compared to the overall results within a group.
Correlations were calculated using Spearman’s correlation co-
efficient (rs). Logistic regression was applied to calculate the
contribution of various variables that could cause discordant
test results. The IBM SPSS software package (version 21) was




A total of 174 healthy individuals were included in this study
and the median age at inclusion was 42.3 years (interquartile
range (IQR): 28.0–53.4). Twenty-seven of 174 (15.5%)
healthy individuals reported antibiotic treatment for Lyme
borreliosis in the past (median of 5.0 years ago; IQR 2.0–
7.0) and were, therefore, classified as treated healthy individ-
uals; 22/27 (81.5%) reported having had an EM, 4/27 (14.8%)
reported a diffuse redness after a tick bite and 1/27 (3.7%)
had flu-like symptoms after a tick bite (Table 1). The me-
dian age at inclusion of the treated healthy individuals was
53.1 years (IQR: 38.3–57.6). The remaining 147/174
(84.5%) individuals were classified as healthy individuals
and had a median age of 40.9 years (IQR: 27.0–51.8) at
inclusion and were younger than the other three groups
(p ≤ 0.001) (Table 1).
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Treated Lyme neuroborreliosis patients
Thirty-six treated Lyme neuroborreliosis patients were includ-
ed and their median age was 59.1 years (IQR: 49.4–66.2)
(Table 1). Most treated Lyme neuroborreliosis patients had
been diagnosed with radiculopathy (n = 24; 66.7%) or cranial
nerve paresis (n = 17; 47.2%), such as facial nerve paralysis
(nerve VII) or abducens nerve palsy (nerve VI). Other diag-
noses included meningitis (n = 2; 5.6%) and peripheral neu-
ropathy (n = 3; 8.3%). Seven patients with radiculopathy also
suffered from facial nerve paralysis, one also had meningitis.
One patient had been diagnosed with facial nerve paralysis
and peripheral neuropathy. Treated Lyme neuroborreliosis pa-
tients were included approximately 6.1 years (IQR: 3.5–8.4)
after antibiotic treatment finished and treatment consisted of
intravenous ceftriaxone for 14 or 30 days; however, one pa-
tient switched to doxycycline (for 14 days) after 10 days due
to an allergic reaction. As many as 33/36 (91.7%) of the treat-
ed Lyme neuroborreliosis patients had a known clinical
outcome; 27 (81.8%) of them had a good recovery and six
(18.2%) of themwere considered a treatment failure (Table 1).
Active Lyme neuroborreliosis patients
Twenty-seven active Lyme neuroborreliosis patients were in-
cluded and their median age was 57.8 years (IQR: 47.8–72.8)
(Table 1). Most active Lyme neuroborreliosis patients were
diagnosed with radiculopathy (n = 8; 29.6%) or cranial nerve
paresis (n = 7; 25.9%), such as facial nerve paralysis or
abducens nerve palsy. Other diagnoses included meningitis
(n = 5; 18.5%) or peripheral neuropathy (n = 2; 7.4%). Four
active Lyme neuroborreliosis patients with radiculopathy also
suffered from facial nerve paralysis, one patient had facial
nerve paralysis and meningitis, and one patient had
radiculopathy as well as peripheral neuropathy. Eight of 27
(29.6%) active Lyme neuroborreliosis patients were, at a later
moment, also included as a treated Lyme neuroborreliosis pa-
tient and were, thus, included in both groups. The median time













Sex; no. of males (%) 57 (38.8) 12 (44.4) 19 (52.8) 14 (51.9) 0.339 NA
Age (at inclusion); median,
years (IQR)
40.9 (27.0–51.8) 53.1 (38.3–57.6) 59.1 (49.4–66.2) 57.8 (47.8–72.8) <0.001 ≤0.001e
Tick bite (%) 86 (58.5) 25 (92.6) 27 (75.0) 9 (56.3)c 0.003 ≤0.008f
EM (%) 4 (2.7) 22 (81.5) 9 (25.0) 4 (25.0)c <0.001 ≤0.004g
Time of inclusion after
AB treatment finished;
median, years (IQR)




NA NA 52.0 (21.0–113.5) 112.0 (33.0–214.0) NA 0.050
Definite LNB; n (%) NA NA 30 (83.3) 22 (81.5) NA 0.553
Possible LNB based on
clinical symptoms and:
NA NA
Pleocytosis; n (%) 1 (2.8) 4 (14.8)
Intrathecal antibody
production; n (%)
5 (13.9) 1 (3.7)
Recovery statush
Good recovery; n (%) 27 (81.8)
Treatment failure; n (%) 6 (18.2)
LNB: Lyme neuroborreliosis; EM: erythema migrans; IQR: interquartile range; AB: antibiotic; NA: not applicable
a One treated healthy individual who did not know when antibiotic treatment took place was excluded
b Eight active Lyme neuroborreliosis patients were also included as treated Lyme neuroborreliosis patients
c Eleven active Lyme neuroborreliosis patients did not fill out the Lyme-specific questionnaire and were, thus, excluded from the calculations
d For all two-group comparisons with a significant difference, the Bonferroni correction was applied (p: 0.050/6 = 0.008)
e Significant difference in age at inclusion for healthy individuals compared to the remaining three groups
f Significant difference in percentage of tick bites for treated healthy individuals compared to healthy individuals and active Lyme neuroborreliosis
patients
g Significant difference in percentage of erythema migrans for healthy individuals compared to the remaining three groups and for treated healthy
individuals compared to treated and active Lyme neuroborreliosis patients
h The clinical outcome could not be established for three treated Lyme neuroborreliosis patients
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between the two blood sampling moments (and, thus, the time
between their inclusion as an active and a treated case) was
2.1 years (IQR: 1.4–2.5). Hence, in total, 63 blood samples
originating from 55 Lyme neuroborreliosis patients were in-
vestigated in this study.
ELISA results
All 27 (100%) active Lyme neuroborreliosis patients had
reactive results for both ELISAs, but the ELISA results
of the other three groups showed more diversity
(Fig. 1). In these three groups, the SERION ELISA
resulted in more reactive cases compared to the C6
ELISA (24 vs. 15), but the difference within each group
was not statistically significant (Fig. 2). The percentage
of reactive ELISA results, when both ELISAs were
combined, was 23.8% (35/147) for healthy individuals,
44.4% (12/27) for treated healthy individuals and 69.4%
(25/36) for treated Lyme neuroborreliosis patients
(Fig. 2). For both healthy individuals and treated
Lyme neuroborreliosis patients, this percentage was sig-
nificantly higher than the percentage of reactive C6
ELISA results alone (26/147 (17.7%) and 16/36
(44.5%), respectively) (p ≤ 0.004 for both) (Figs. 1
and 2). For treated Lyme neuroborreliosis patients, the
percentage of reactive results of the C6 ELISA and the
SERION ELISA combined (25/36; 69.4%) was also sig-
nificantly higher than the percentage of reactive results
of the SERION ELISA alone (18/36; 50.0%) (p =
0.016) (Figs. 1 and 2).
Concordance of ELISA results
The concordance between both ELISAs was lower for
treated healthy individuals (18/27; 66.7%) and treated
Lyme neuroborreliosis patients (18/36; 50.0%) than for
healthy individuals (131/147; 89.1%) and active Lyme
neuroborreliosis patients (26/27; 96.3%) (p ≤ 0.005)
(Fig. 3a). The majority of the concordant ELISA results
were based on negative ELISA results, except for ac-
tive Lyme neuroborreliosis patients, for whom only re-
active ELISA results were found. In contrast, 112/131
(85.5%) ELISA results among healthy individuals were
concordant negative (Fig. 2), of whom only three
(2.3%) reported a previous (untreated) EM (data not
shown). Although it was unclear whether healthy indi-
viduals had been infected with Borrelia in the past, the
percentage of concordant negative results among healthy
individuals did not differ from the percentage of concor-
dant negative results among treated healthy individuals or
treated Lyme neuroborreliosis patients (15/18 (83.3%) and
11/18 (61.1%), respectively) (Fig. 2).
Immunoblot results
In total, 99 immunoblots had to be performed based on 44






















































































Fig. 1 Overall view of the proportions of reactive (equivocal and
positive) enzyme-linked immunosorbent assay (ELISA) and test strategy
results. LNB: Lyme neuroborreliosis. The black bars represent positive
results and the shaded bars represent equivocal results. C6: C6 ELISA;
C6/IB: C6 ELISA plus immunoblot strategy; SE SERION ELISA; SE/
IB: SERION ELISA plus immunoblot strategy; SE + C6: combination of
SERION ELISA and C6 ELISA; SE + C6/IB: SERION ELISA, C6
ELISA plus immunoblot strategy. The C6 + SE bars represent the
percentage of reactive results for at least one of the tests (i.e. C6
ELISA, SERION IgM ELISA or SERION IgG ELISA). Only statistical
significant differences are displayed. */#: Significant difference between
the ELISAs (*) and the test strategies (#) in the overall dataset; **:
Significant difference between the two-group comparisons of the
ELISAs. For all two-group comparisons with a significant difference,
the Bonferroni correction was applied (p: 0.050/3 = 0.017)
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r e s u l t s ( F i g . 2 ) . A l l 27 ( 100%) a c t i v e Lyme
neuroborreliosis patients were confirmed by immunoblot
analysis. A lower percentage of confirmed cases was found
among the other three groups. Of the 35 healthy individ-
uals that had a reaction with one or both ELISAs, 20
(57.1%) were confirmed by immunoblot; among treated
healthy individuals, this was 75.0% (9/12) and among
treated Lyme neuroborreliosis patients, it was 40.0% (10/
25) (Fig. 2).
With regard to the 55 concordant reactive ELISA results,
53 (96.4%) were confirmed by immunoblot. All 53 had a
positive result for the C6 ELISA and the SERION IgG
ELISA, of which 31 (58.5%) also had an equivocal or positive
result for the SERION IgM ELISA. Immunoblot confirmation
was based on an IgG response against at least two antigens;
IgG against VlsE was found in all 53 cases, followed by IgG
against p41 flagellin (39/53; 73.6%) and subsequently by IgG
against p100, p18, p58, p39 and OspC (range 23 to 9;
43.3% to 17.0%) (data not shown). Only 16/53 (30.2%)
cases were also confirmed based on the presence of IgM,
of which most cases were found among active Lyme
neuroborreliosis patients (13/16; 81.3%). For all 16 IgM
confirmed cases, antibodies were found against OspC,
followed by IgM against p41 flagellin (11/16; 68.8%) (data
not shown). The remaining 2/55 (3.6%) concordant reac-
tive ELISA results were not confirmed. One case was a
healthy individual with an equivocal result for both the
C6 ELISA and the SERION IgM ELISA, and the other
case was a treated Lyme neuroborreliosis patient with a
positive result for both the C6 ELISA and the SERION
IgM ELISA (Fig. 2).
Analysis of the 44 discordant ELISA results showed that
most cases were SERION ELISA reactive/C6 ELISA nega-
tive (n = 24; 54.5%) (Fig. 2). Those cases were based on
reactivity for the SERION IgM ELISA alone (n = 16/24;
66.6%), for the SERION IgG ELISA alone (3/16; 18.8%) or
for both the SERION IgM and the SERION IgG ELISAs
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Fig. 2 Detailed view of the different ELISA and test strategy results.
LNB: Lyme neuroborreliosis. The black boxes represent positive
results, the shaded boxes represent equivocal results and the white
boxes represent negative results. C6: C6 ELISA; C6/IB: C6 ELISA plus
immunoblot strategy; SE: SERION ELISA; SE/IB: SERION ELISA plus
immunoblot strategy; SE + C6: combination of SERION ELISA and C6









































p 0.005** p <0.001**
p <0.001**
p <0.001#
Fig. 3 The concordance between the results of the C6 ELISA and the
results of the SERION ELISA (a) and the concordance between the
results of the C6 ELISA plus immunoblot strategy and the SERION
ELISA plus immunoblot strategy (b). HI: healthy individuals; THI:
treated healthy individuals; TNB: treated Lyme neuroborreliosis
patients; ANB: active Lyme neuroborreliosis patients; n: number of
study subjects. Only statistical significant differences are displayed. For
all two-group comparisons with a significant difference, the Bonferroni
correction was applied (p: 0.050/6 = 0.008). */#: Significant difference
between the ELISAs (*) and the test strategies (#) in the overall dataset;
**: Significant difference between the two-group comparisons of the
ELISAs
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results were confirmed, of which only two were based on C6
ELISA reactive/SERION ELISA negative results.
Interestingly, none of the 15 C6 ELISA reactive/SERION
ELISA negative results showed a VlsE band. Immunoblot
confirmation of the two cases was based on the presence of
IgM against OspC (n = 2) and p41 flagellin (n = 1) (data not
shown). In total, 10/24 (41.7%) SERION ELISA reactive/C6
ELISA negative results were confirmed. Five (31.3%) out of
the 16 solitary IgM reactive cases were confirmed based on
IgM against OspC (n = 5) and p41 flagellin (n = 1); one also
had IgG against OspC and p41 flagellin. One (33.3%) out of
the three solitary IgG cases was confirmed based on IgG
against p41 flagellin and p18, and 4/5 (80.0%) IgM and IgG
reactive cases were confirmed. Two cases had IgM against
OspC and p41 flagellin, of whom the second case also had
IgG against VlsE and p18, the third case had IgG against
OspC and p41 flagellin, and the fourth case had IgG against
VlsE and p39 (data not shown). The remaining confirmed
case was an active neuroborreliosis patient who had
reactive—but discordant—ELISA results. Immunoblot
analysis showed IgG against VlsE, p41 flagellin and p39 (data
not shown).
Concordance of test strategy results
For all groups, the concordance between the C6/IB strategy
and the SE/IB strategy was higher than the concordance found
between both ELISAs. Only for treated healthy individuals
was the concordance still significantly lower than for healthy
individuals (21/27 (77.8%) and 145/147 (98.6%), respective-
ly) (p < 0.001) (Fig. 3b). Interestingly, no correlation was
found between the C6 ELISA reactive/SERION ELISA neg-
ative results and the immunoblot results (rs = 0.154; p =
0.584), but a correlation was found between the SERION
ELISA reactive/C6 ELISA negative results and the immuno-
blot results (rs = 0.555; p = 0.005). Thus, reactive SERION
ELISA results were more often confirmed by immunoblot
analysis than the reactive C6 ELISA results.
Possible explanations for the discordant ELISA and test
strategy results
Discordant ELISA results are caused by variability in the
amount and type of antibodies, which, in turn, may be influ-
enced by antibiotic treatment and/or the natural course of
clearance of infection. The natural course of clearance of in-
fection may be influenced by the age, sex or recovery of the
patient, whether or not a tick bite or EM were observed, the
time between end of antibiotic treatment and blood sampling
and duration of symptoms before the start of antibiotic thera-
py. We determined the possible contribution of these factors to
the discordance of test results. Analysis of all study participants
showed that only antibiotic treatment was strongly associated
with discordant ELISA and discordant test strategy results
[odds ratio (OR): 10.52; [ < 0.001 and OR: 9.98; p = 0.014,
respectively] (Table 2). Among healthy individuals and Lyme
neuroborreliosis patients who were both treated, the time be-
tween the end of antibiotic treatment and blood sampling did
not contribute to an increased discordance (data not shown).
However, solely among treated Lyme neuroborreliosis patients,
the C6 ELISA index scores did decrease with increasing time
between the end of antibiotic treatment and blood sampling
(rs = −0.408; p = 0.013). For the SERION IgMand SERION IgG
ELISAs, and among treated healthy individuals, we did not
find such a correlation (data not shown). When both treated
groups were analysed separately, older age was associated
with a slight increase in the percentage of discordant ELISA
results among treated Lyme neuroborreliosis patients (OR:
1.10; p = 0.015). In contrast, older age was associated with a
lower percentage of discordant test strategy results among
treated Lyme individuals, although only slightly (OR: 0.82;
p = 0.033). There was no association between the recovery
status or the duration of symptoms and the percentage of dis-
cordant ELISA or test strategy results among treated Lyme
neuroborreliosis patients (data not shown).
Discussion
In this study, we compared two standard two-tier test strate-
gies by using two screening ELISAs and a conformational
immunoblot on various well-defined Dutch Lyme patients
and healthy individuals. High concordances between the re-
sults of the test strategies were found for healthy individuals
and active Lyme neuroborreliosis patients groups (range 98.6–
100%); however, low concordances were observed for Lyme
neuroborreliosis patients and healthy individuals who had
been treated for Lyme borreliosis in the past (range 77.8–
88.9%). Discordant test results represent variability in the
amount and type of antibodies, which, in turn, may be influ-
enced by antibiotic treatment and/or the natural course of
clearance of infection. Of the investigated factors affecting
the natural clearance of the infection, only age contributed to
discordant ELISA or test strategy results within both treated
groups, but only to a minimal extent. Older age was associated
with an increase of discordant ELISA results among treated
Lyme neuroborreliosis patients and with a decrease of discor-
dant test strategy results among treated healthy individuals.
The significantly higher discordance between the ELISA re-
sults in the two treated groups compared to the almost concor-
dant ELISA results in active Lyme neuroborreliosis patients
(96.3%) and healthy individuals (89.1%) was associated to
antibiotic treatment against Lyme borreliosis. This suggests
that antibiotic treatment influences the pace at which the de-
tected serum antibodies wane.
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Furthermore, this study showed that the SERION ELISA
had more positive results than the C6 ELISA and also led to a
higher percentage of immunoblot-confirmed results. This
finding implies that serum antibodies against the C6 peptide
wane faster than other Borrelia-specific serum antibodies. In
this study, we found a significant correlation among treated
Lyme neuroborreliosis patients between the decrease in C6
ELISA index scores and a longer time between the end of
antibiotic treatment and blood sampling. Although the number
of cases in our study is small, other studies also showed a
decline of C6 antibodies and a >4-fold decrease in C6
ELISA results within one year after antibiotic treatment [20,
21]. In 9/13 (69.2%) immunoblot-confirmed sera, for which
discordant ELISA results were found, the presence of IgM
against OspC, and in some cases p41 flagellin, was found.
In 10/13 cases (76.9%), confirmation was based on a reactive
SERION ELISA result only. Since both OspC and p41 flagel-
lin are part of the whole-cell lysate used in the SERION
ELISA, this might explain the higher positive rate for this
ELISA. Aguero-Rosenfeld et al. [22] also reported the persis-
tence of IgM against OspC and p41 flagellin in more than half
of the patients in their study during a follow-up at one year.
The persistence of the immune response against OspC and
p41 flagellin up to 20 years after successful treatment has also
been described byKalish et al. [4]. To emphasise, the presence
of Borrelia-specific serum antibodies is no proof of an active
Lyme borreliosis infection or proof of a false-positive reaction
of the ELISA used, but could well be explained by a previous,
cleared Lyme borreliosis infection, with or without antibiotic
treatment.
Surprisingly, all 15 reactive C6 ELISA results with nega-
tive SERION ELISA results failed to show a VlsE band in the
immunoblot analysis. A C6 ELISA positivity could be
expected, since 10/15 (66.7%) cases were treated for Lyme
borreliosis in the past, but the absence of a VlsE band for all
cases was unexpected. It could be explained by a reduced
sensitivity of the immunoblot [23] or by a difference in the
accessibility of the C6 peptide on the immunoblot. The C6
peptide is not exposed on the surface of VlsE and becomes
available only when VlsE is processed after a Borrelia infec-
tion has occurred and it is, therefore, suggested that C6 elicits
a different antibody response compared to VlsE, which is
supported by this study [12, 15].
Although this study underlines the importance of the two-
tier test strategy, the analysis of the third strategy, SE + C6/IB,
was also of interest, as this strategy resulted in the highest
number of sera for which Borrelia-specific serum antibodies
were detected. A disadvantage was the high number of immu-
noblot tests that were needed to get the final results. The strat-
egy could be simplified by not confirming concordant positive
ELISA results with immunoblot. This simplified SE + C6/IB
would substantially decrease the number of immunoblots
needed from 99 to 45 (−54.5%), which is also less compared
to the C6/IB strategy (45 vs. 75 (−40.0%)) or the SE/IB strat-
egy alone (45 vs. 84 (−46.4%)). The final results would almost
be similar, as only one treated neuroborreliosis patient would
be recorded differently (both ELISAs positive/immunoblot
negative). Since the immunoblot is more labour-intensive, ex-
pensive and the interpretation more subjective compared to an
ELISA, this simplified SE + C6/IB strategy is interesting, as
other studies also underline the potential of a two-ELISA
strategy for the diagnosis of Lyme borreliosis [24, 25].
The selection criteria used in our study ruled out the inclu-
sion of other than Lyme neuroborreliosis patients. Since Lyme
neuroborreliosis is the most common clinical presentation of
disseminated Lyme borreliosis in the Netherlands and the
Table 2 Logistic regression model assessing risk factors for discordant test results among study participants
Test Parameter B SE Wald df p-Value Odds ratio 95% CI for OR
Lower Upper
ELISAs Sex (male) −0.15 0.37 0.17 1 0.684 0.86 0.42 1.78
Tick bite (yes) −0.49 0.42 1.38 1 0.240 0.61 0.27 1.39
EM (yes) −0.65 0.50 1.70 1 0.193 0.52 0.19 1.39
Antibiotic treatment (yes) 2.35 0.49 23.49 1 <0.001a 10.52 4.06 27.26
Age 0.01 0.01 0.21 1 0.647 1.01 0.98 1.03
Test strategies Sex (male) −0.47 0.64 0.54 1 0.462 0.62 0.18 2.20
Tick bite (yes) −0.83 0.74 1.26 1 0.262 0.44 0.10 1.86
EM (yes) 0.78 0.72 1.15 1 0.283 2.17 0.53 8.97
Antibiotic treatment (yes) 2.30 0.93 6.10 1 0.014a 9.98 1.61 61.92
Age −0.02 0.02 0.94 1 0.333 0.98 0.93 1.02
The logistic regressionmodel gives the probability that a discordant test result will be found (n = 226; 11 active Lyme neuroborreliosis patients did not fill
out the Lyme-specific questionnaire and were, thus, excluded from the calculations). B: coefficient for the constant; SE: standard error; df: degrees of
freedom for the Wald Chi-square test; CI: confidence interval; OR: odds ratio
a Statistically significant
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criteria for Lyme neuroborreliosis, as proposed by the EFNS
[16], are clear and easy to apply, this ensured the inclusion of
true Lyme neuroborreliosis cases. A potential bias could be
the lower age of the healthy individuals compared to the other
three groups. Furthermore, eight patients were included twice
in this study, both as an active Lyme neuroborreliosis patient
and later as a treated Lyme neuroborreliosis patient.
Nevertheless, we argue that the influence of these potential
biases are limited, since they most likely do not affect the
performance of the ELISAs and the immunoblot, or, if so,
the possible effect should be equal for all tests concerned.
Finally, the number of study participants in our study is limit-
ed and future studies including more patients and healthy con-
trols, as well as different Lyme manifestations, are needed to
strengthen our findings. Future studies could also investigate
the effect of the host immune response and the infecting
Borrelia species on test results.
To conclude, this study showed a lower test agreement in
healthy individuals and Lyme neuroborreliosis patients who
were both treated for Lyme borreliosis in the past. We showed
that antibiotic treatment influences serological test results and
that the effect differs for the different assays. Although the
number of cases is limited and we did not take into account
the possible influence of the different clinical manifestations,
we do believe that antibiotics contribute to the variation in the
kinetics of the antibodies directed against the different
Borrelia antigens used in the tests. Although only two com-
mercial ELISAs and one commercial immunoblot were tested,
our data suggest that this holds true for other assays based on
different antigens and/or different Borrelia strains. This study
emphasises that care should be taken when Lyme serology is
considered and symptoms are non-specific. It supports the
general opinion that serological testing for Borrelia-specific
serum antibodies should only be performed in case of a high a
priori chance of Lyme borreliosis. To our knowledge, this is
the first study that gives an in-depth insight into the diagnostic
challenges which arise when individuals have been treated for
Lyme borreliosis in the past.
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